Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.

Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV), JM216, is the first antineoplastic platinum compound that can be given to patients orally. Several phase II clinical trials of JM216 monotherapy have already been reported. However, no information on the potential drug interactions caused by...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Y., Shimizu, T., Nakamura, K., Mushiroda, T., Nakagawa, T., Kodama, T., Kamataki, T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062991/
https://www.ncbi.nlm.nih.gov/pubmed/9820175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062991/
https://www.ncbi.nlm.nih.gov/pubmed/9820175

Ejemplares similares